^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AXT-1003

    i
    Other names: AXT-1003, AXT1003, AXT 1003
    Associations

    News

    Trials
    Company:
    Axter Therap, Novartis
    Drug class:
    EZH2 selective degrader
    Related drugs:
    Associations

    News

    Trials
    1year
    Study of AXT-1003 in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=78, Recruiting, Axter Therapeutics (Beijing) Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AXT-1003
    over1year
    Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=1, Terminated, Axter Therapeutics (Beijing) Co., Ltd | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    AXT-1003
    over1year
    Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=1, Terminated, Axter Therapeutics (Beijing) Co., Ltd | N=79 --> 1 | Trial completion date: Jan 2026 --> Jun 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jun 2024; Due to the adjustment of the protocol and expansion of the indication population, a new clinical trial protocol was submitted to the Health Authority, so the registration was conducted as a new clinical trial and this trial was terminated.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    AXT-1003
    over1year
    Study of AXT-1003 in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=78, Not yet recruiting, Axter Therapeutics (Beijing) Co., Ltd
    New P1 trial • Metastases
    |
    AXT-1003
    over2years
    Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=79, Recruiting, Axter Therapeutics (Beijing) Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    AXT-1003
    over2years
    Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=79, Not yet recruiting, Axter Therapeutics (Beijing) Co., Ltd
    New P1 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    AXT-1003